Replies to post #32319 on Cel Sci Corporation (CVM)

[Biobonic]

The next reason for shorts is the success/failure rate in oncology.

Disease areas covered in this report:
• Allergy
• Autoimmune
• Cardiovascular
• Chronic High Prevalence Diseases
• Endocrine
• Gastroenterology
• Hematology
• Infectious Disease
• Metabolic
• Neurology
• Oncology
• Ophthalmology
• Psychiatry
• Rare Diseases
• Respiratory
• Urology

The success of an Oncology (tumors) biotech from a Phase 3 to BLA is 40%.

The lowest percent of all those Disease areas listed.

And tell me, has CVM had smooth sailing in the Phase 3?

Fire a CRO, take them to court!

FDA clinical hold.

Then the late admission of an IDMC recommendation to shut it down.

The CEO amending the trial prior to FDA approval.(Upping the participants)

Raising money at 79 cents a share.

25 to 1 Reverse Split.

So cash poor that it pays some bills by issuing stock.



Yeah, from the outside this is the perfect short...